FDA
-
-
-
-
-
-
-
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
-
-
-
-
-
-
-
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
-
-
-
-
-
-
-
Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024
-
-
-
-
-
-
-
Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
-
-
-
-
-
-
-
Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update
-
-
-
-
-
-
-
Innate Pharma: SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies
-
-
-
-
-
-
-
Innate Pharma Reports Third Quarter 2020 Financial Results and Business Update
-
330,722 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

